tirzepatide in an antonio Home | La Femme OB/GYN, 43 pounds down—and this is

A previous single-case report revealed tirzepatide-induced euglycemic ketoacidosis in nondiabetic patients [5]

Ludovico Di Gioia, Endocrinology Unit, Regional General Hospital Francesco Miulli, Acquaviva delle Fonti, IT 70021 Bari, Italy

Abstract Case series Patients: Female, 29-year-old Female, 34-year-old Female, 17-year-old Female, 26-year-old Final Diagnosis: Tirzepatide-induced hypoglycemic ketoacidosis for weight loss in four nondiabetic patients Symptoms: Diarrhea vomiting Clinical Procedure: Fluid replacement Specialty: Critical Care Medicine Objective: Unusual clinical course Background: Tirzepatide is a long-acting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist administered via subcutaneous injection for weight reduction and treating type 2 diabetes

This treatment is often recommended for: Individuals With Obesity Those with a BMI (Body Mass Index) of 30 or higher

Insulin and glucagon work in a counteractive mode to regulate glucose metabolism

Patients with heart failure, kidney disease, or hypertension should follow their healthcare provider's specific recommendations regarding fluid and sodium intake